{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:16:31Z","timestamp":1792826191566,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Ticagrelor is a commonly used antiplatelet agent, but due to the stringent criteria for trial population inclusion and the limited sample size, its safety profile has not been fully elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>We utilized OpenVigil 2.1 to query the FDA Adverse Event Reporting System database and retrieved reports by the generic name \u201cticagrelor\u201d published between 1 October 2010 and 31 March 2023. Adverse drug events (ADEs) were classified and described according to the preferred terms and system organ classes in the Medical Dictionary of Regulatory Activity. Proportional reporting ratio (PRR), reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) were used to detect signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The number of ADE reports with ticagrelor as the primary suspect drug was 12,909. The top three ADEs were dyspnea [1824 reports, ROR 7.34, PRR 6.45, information component (IC) 2.68], chest pain (458 reports, ROR 5.43, PRR 5.27, IC 2.39), and vascular stent thrombosis (406 reports, ROR 409.53, PRR 396.68, IC 8.02). The highest ROR, 630.24, was found for \u201cvascular stent occlusion\u201d. Cardiac arrest (137 reports, ROR 3.41, PRR 3.39, IC 1.75), atrial fibrillation (99 reports, ROR 2.05, PRR 2.04, IC 1.03), asphyxia (101 reports, ROR 23.60, PRR 23.43, IC 4.51), and rhabdomyolysis (57 reports, ROR 2.75, PRR 2.75, IC 1.45) were suspected new adverse events of ticagrelor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The FAERS database produced potential signals associated with ticagrelor that have not been recorded in the package inserts, such as cardiac arrest, atrial fibrillation, asphyxia, and rhabdomyolysis. Further clinical surveillance is needed to quantify and validate potential hazards associated with ticagrelor-related adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1251961","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:39:15Z","timestamp":1712637555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor"],"prefix":"10.3389","volume":"15","author":[{"given":"Yunyan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s43440-021-00309-0","article-title":"A review of the effects of ticagrelor on adenosine concentration and its clinical significance","volume":"73","author":"Akkaif","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.14740\/jmc3815","article-title":"Heart block caused by ticagrelor use in a patient who underwent adenosine diastolic fractional reserve assessment: a case report","volume":"12","author":"Al-Bayati","year":"2021","journal-title":"J. Med. Cases"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3906\/sag-1903-188","article-title":"Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel","volume":"49","author":"Alg\u00fcl","year":"2019","journal-title":"Turk J. Med. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0218492320981483","article-title":"A rare case of late-onset ticagrelor-induced sinus arrest","volume":"29","author":"Aranganathan","year":"2021","journal-title":"Asian Cardiovasc Thorac. Ann."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e020446","DOI":"10.1161\/jaha.120.020446","article-title":"Long-term ticagrelor in patients with prior coronary stenting in the PEGASUS-TIMI 54 trial","volume":"10","author":"Bergmark","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial","volume":"50","author":"Cannon","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","unstructured":"Labeling-package insert of ticagrelor (BRILINTA)2019"},{"key":"B15","unstructured":"Labeling-package insert of ticagrelor (BRILINTA)2020"},{"key":"B16","unstructured":"Labeling-package insert of ticagrelor (BRILINTA)2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1055\/s-0042-1749589","article-title":"Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond","volume":"48","author":"George","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/apt.15059","article-title":"Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y(12) inhibitors compared with clopidogrel","volume":"49","author":"Guo","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur. Heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1331\/JAPhA.2015.14151","article-title":"Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin","volume":"55","author":"Kido","year":"2015","journal-title":"J. Am. Pharm. Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.7759\/cureus.12874","article-title":"Ticagrelor-induced syncope\/bradyarrhythmia","volume":"13","author":"Kotaru","year":"2021","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/cts.13596","article-title":"Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018","volume":"16","author":"Kumar","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.sleep.2021.01.026","article-title":"Central sleep apnea after acute coronary syndrome and association with ticagrelor use","volume":"80","author":"Meurin","year":"2021","journal-title":"Sleep. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-018-2482-9","article-title":"A comprehensive review and meta-analysis of risk factors for statin-induced myopathy","volume":"74","author":"Nguyen","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/2048872614554108","article-title":"Dyspnoea management in acute coronary syndrome patients treated with ticagrelor","volume":"4","author":"Parodi","year":"2015","journal-title":"Eur. Heart J. Acute Cardiovasc Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105089","DOI":"10.1016\/j.phrs.2020.105089","article-title":"Risk of bradyarrhythmia related to ticagrelor: a systematic review and meta-analysis","volume":"160","author":"Pujade","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.jacc.2018.03.447","article-title":"Ticagrelor and central sleep apnea","volume":"71","author":"Revol","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07459-8","article-title":"Rhabdomyolysis with Co-administration of statins and antiplatelet therapies-analysis of the WHO pharmacovigilance database","author":"Roule","year":"2023","journal-title":"Cardiovasc Drugs Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ahj.2018.04.020","article-title":"Safety of ticagrelor in patients with baseline conduction abnormalities: a PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis","volume":"202","author":"Scirica","year":"2018","journal-title":"Am. Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.jacc.2010.11.056","article-title":"The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy","volume":"57","author":"Scirica","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000350961","article-title":"Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive","volume":"126","author":"Serebruany","year":"2013","journal-title":"Cardiology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"990241","DOI":"10.3389\/fphar.2022.990241","article-title":"Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database","volume":"13","author":"Shu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","article-title":"Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","article-title":"Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers","volume":"69","author":"Teng","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2022.2078301","article-title":"Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review","volume":"21","author":"Tian","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bcpt.13035","article-title":"Rosuvastatin-induced rhabdomyolysis - possible role of ticagrelor and patients' pharmacogenetic profile","volume":"123","author":"Vrki\u0107 Kirhmajer","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/s0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12872-018-0948-4","article-title":"Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cardiovasc Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","article-title":"Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database","volume":"45","author":"Wei","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijcard.2016.03.091","article-title":"Another side effect of ticagrelor: atrial fibrillation","volume":"212","author":"Zhang","year":"2016","journal-title":"Int. J. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1251961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:39:19Z","timestamp":1712637559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1251961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":47,"alternative-id":["10.3389\/fphar.2024.1251961"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1251961","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"article-number":"1251961"}}